{
    "id": 14023,
    "fullName": "NOTCH1 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "NOTCH1 mutant indicates an unspecified mutation in the NOTCH1 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 4851,
        "geneSymbol": "NOTCH1",
        "terms": [
            "NOTCH1",
            "AOS5",
            "AOVD1",
            "hN1",
            "TAN1"
        ]
    },
    "variant": "mutant",
    "createDate": "11/18/2015",
    "updateDate": "10/08/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 3668,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF-03084014 treatment resulted in tumor regression in patient-derived xenograft models of triple receptor negative breast cancer harboring NOTCH1 mutations (PMID: 25564152).",
            "molecularProfile": {
                "id": 14278,
                "profileName": "NOTCH1 mutant"
            },
            "therapy": {
                "id": 859,
                "therapyName": "PF-03084014",
                "synonyms": null
            },
            "indication": {
                "id": 60081,
                "name": "triple-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3942,
                    "pubMedId": 25564152,
                    "title": "PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a \u03b3-secretase inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25564152"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16820,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (AIM), distinct molecular profiles were identified in mantle cell lymphoma patients responded to Imbruvica (ibrutinib) and Venclexta (venetoclax) combination therapy compared to those did not respond, with all patients harboring mutations in NSD2 (n=4), UBR5 (n=3), KMT2D (n=3), and 12 of 13 patients harboring mutations in ATM responded to the therapy, while SMARCA4 (n=4), CCND1 (n=2), and NOTCH1 (n=3) alterations were exclusively observed in nonresponders (PMID: 30455436; NCT02471391).",
            "molecularProfile": {
                "id": 14278,
                "profileName": "NOTCH1 mutant"
            },
            "therapy": {
                "id": 3392,
                "therapyName": "Ibrutinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14918,
                    "pubMedId": 30455436,
                    "title": "Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30455436"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 10046,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Kisqali (ribociclib) and Omnipred (prednisolone) resulted in a synergistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).",
            "molecularProfile": {
                "id": 27228,
                "profileName": "NOTCH1 mut RB1 wild-type"
            },
            "therapy": {
                "id": 5356,
                "therapyName": "Prednisolone + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 5602,
                "name": "T-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7921,
                    "pubMedId": 28151717,
                    "title": "Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28151717"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10037,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Kisqali (ribociclib) to Elspar (asparaginase) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).",
            "molecularProfile": {
                "id": 27228,
                "profileName": "NOTCH1 mut RB1 wild-type"
            },
            "therapy": {
                "id": 5354,
                "therapyName": "Asparaginase + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 5602,
                "name": "T-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7921,
                    "pubMedId": 28151717,
                    "title": "Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28151717"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10031,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a T-cell acute lymphoblastic leukemia cell line co-harboring wild-type RB1 and a NOTCH1 mutation demonstrated sensitivity to treatment with Kisqali (ribociclib) in culture, resulting in inhibition of cell growth (PMID: 28151717).",
            "molecularProfile": {
                "id": 27228,
                "profileName": "NOTCH1 mut RB1 wild-type"
            },
            "therapy": {
                "id": 790,
                "therapyName": "Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 5602,
                "name": "T-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7921,
                    "pubMedId": 28151717,
                    "title": "Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28151717"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10033,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Kisqali (ribociclib) to Methotrexate resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).",
            "molecularProfile": {
                "id": 27228,
                "profileName": "NOTCH1 mut RB1 wild-type"
            },
            "therapy": {
                "id": 5352,
                "therapyName": "Methotrexate + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 5602,
                "name": "T-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7921,
                    "pubMedId": 28151717,
                    "title": "Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28151717"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10050,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Kisqali (ribociclib) and JQ1 resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).",
            "molecularProfile": {
                "id": 27228,
                "profileName": "NOTCH1 mut RB1 wild-type"
            },
            "therapy": {
                "id": 5357,
                "therapyName": "JQ1 + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 5602,
                "name": "T-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7921,
                    "pubMedId": 28151717,
                    "title": "Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28151717"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10043,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Kisqali (ribociclib) and Adexone (dexamethasone) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased cell viability and reduced phosphorylation of Rb1 in culture, and a greater survival benefit in xenograft models when compared to Kisqali (ribociclib) alone (PMID: 28151717).",
            "molecularProfile": {
                "id": 27228,
                "profileName": "NOTCH1 mut RB1 wild-type"
            },
            "therapy": {
                "id": 5355,
                "therapyName": "Dexamethasone + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 5602,
                "name": "T-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7921,
                    "pubMedId": 28151717,
                    "title": "Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28151717"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10035,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Kisqali (ribociclib) to Purixan (mercaptopurine) resulted in an antagonistic effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).",
            "molecularProfile": {
                "id": 27228,
                "profileName": "NOTCH1 mut RB1 wild-type"
            },
            "therapy": {
                "id": 5353,
                "therapyName": "Mercaptopurine + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 5602,
                "name": "T-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 7921,
                    "pubMedId": 28151717,
                    "title": "Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28151717"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 10052,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Kisqali (ribociclib) and Velcade (bortezomib) resulted in an additive effect in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation in culture (PMID: 28151717).",
            "molecularProfile": {
                "id": 27228,
                "profileName": "NOTCH1 mut RB1 wild-type"
            },
            "therapy": {
                "id": 5358,
                "therapyName": "Bortezomib + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 5602,
                "name": "T-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7921,
                    "pubMedId": 28151717,
                    "title": "Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28151717"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10048,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Kisqali (ribociclib) and Afinitor (everolimus) treatment in a T-cell acute lymphoblastic leukemia cell line harboring wild-type RB1 and a NOTCH1 mutation resulted in decreased Rb1 phosphorylation and a greater inhibition of cell growth compared to either agent alone in culture (PMID: 28151717).",
            "molecularProfile": {
                "id": 27228,
                "profileName": "NOTCH1 mut RB1 wild-type"
            },
            "therapy": {
                "id": 5073,
                "therapyName": "Everolimus + Ribociclib",
                "synonyms": null
            },
            "indication": {
                "id": 5602,
                "name": "T-cell adult acute lymphocytic leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7921,
                    "pubMedId": 28151717,
                    "title": "Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28151717"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 14278,
            "profileName": "NOTCH1 mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 14279,
            "profileName": "ERBB2 neg ESR1 neg NOTCH1 mut PGR neg",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 27228,
            "profileName": "NOTCH1 mut RB1 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}